Page 16 - Read Online
P. 16

Schaafsma et al. J Cancer Metastasis Treat 2021;7:34  https://dx.doi.org/10.20517/2394-4722.2021.72  Page 11 of 12

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century.
                   J Clin Oncol 2010;28:2625-34.  DOI  PubMed  PMC
               2.       Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078.  DOI  PubMed
               3.       Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.  DOI  PubMed  PMC
               4.       Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature
                   2008;455:930-5.  DOI  PubMed  PMC
               5.       Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004;75:727-
                   30.  DOI  PubMed  PMC
               6.       Yan P, Qi F, Bian L, et al. Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United
                   States: a Surveillance, Epidemiology, and End Results (SEER) program population study. Med Sci Monit 2020;26:e927218.  DOI
                   PubMed  PMC
               7.       Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.  DOI  PubMed  PMC
               8.       Yu AL, Gilman AL, Ozkaynak MF, et al; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and
                   isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.  DOI  PubMed  PMC
               9.       Zhang P, Wu X, Basu M, et al. MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico
                   immunological analysis of TARGET database. Front Immunol 2017;8:1473.  DOI  PubMed  PMC
               10.      Wei JS, Kuznetsov IB, Zhang S, et al. Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-Cell receptors in
                   high-risk MYCN-not-amplified human neuroblastoma. Clin Cancer Res 2018;24:5673-84.  DOI  PubMed  PMC
               11.      Layer JP, Kronmüller MT, Quast T, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic
                   neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology 2017;6:e1320626.  DOI  PubMed
                   PMC
               12.      Zhong X, Zhang Y, Wang L, Zhang H, Liu H, Liu Y. Cellular components in tumor microenvironment of neuroblastoma and the
                   prognostic value. PeerJ 2019;7:e8017.  DOI  PubMed  PMC
               13.      Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression
                   or malignant progression in neuroblastomas. Genome Biol 2008;9:R150.  DOI  PubMed  PMC
               14.      Oberthuer A, Juraeva D, Li L, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting
                   clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010;10:258-66.  DOI  PubMed  PMC
               15.      Henrich KO, Bender S, Saadati M, et al. Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional
                   deregulation in unfavorable neuroblastomas. Cancer Res 2016;76:5523-37.  DOI  PubMed
               16.      Munro SA, Lund SP, Pine PS, et al. Assessing technical performance in differential gene expression experiments with external spike-in
                   RNA control ratio mixtures. Nat Commun 2014;5:5125.  DOI  PubMed
               17.      Kocak H, Ackermann S, Hero B, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous
                   regression in neuroblastoma. Cell Death Dis 2013;4:e586.  DOI  PubMed  PMC
               18.      Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that
                   multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-62.  DOI  PubMed
               19.      Rajbhandari P, Lopez G, Capdevila C, et al. Cross-cohort analysis identifies a TEAD4-MYCN positive feedback loop as the core
                   regulatory element of high-risk neuroblastoma. Cancer Discov 2018;8:582-99.  DOI  PubMed  PMC
               20.      Łastowska M, Viprey V, Santibanez-Koref M, et al. Identification of candidate genes involved in neuroblastoma progression by
                   combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-44.  DOI  PubMed
               21.      Ackermann S, Cartolano M, Hero B, et al. A mechanistic classification of clinical phenotypes in neuroblastoma.  Science
                   2018;362:1165-70.  DOI  PubMed  PMC
               22.      Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage
                   neuroblastoma. Cancer Cell 2002;2:377-86.  DOI  PubMed
               23.      Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.  DOI  PubMed
                   PMC
   11   12   13   14   15   16   17   18   19   20   21